Marinomed Biotech AG: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay fever
Verfasser: PRandD on Tuesday, 26 November 2019• Phase III study comparing Budesolv with standard treatment:
Budesolv acts faster against allergic nasal symptoms and asthma-associated symptoms
Budesolv requires 85% less active ingredient for the same effect
Data presented for the first time at the annual meeting of the American College of Allergy, Asthma & Immunology, Houston, Texas
Vienna (Austria), 26. November 2019. Marinomed Biotech AG (Marinomed) has presented detailed data from its pivotal Phase III clinical trial for the therapeutic comparability of an aqueous solution of budesonide, a synthetic steroid for the treatment of hay fever. A nasal spray, referred to as Budesolv, is the current lead product of the company's Marinosolv® technology platform, which enables complete solubilization of difficult-to-dissolve substances, such as steroids. For the first time detailed evaluations of the data on the treatment of 75 patients were shown at the annual meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Houston, Texas. Allergy patients received Budesolv, Rhinocort Aqua (a licensed, suspension-based comparator) or placebo once daily for 8 days. Patients were exposed to grass pollen under controlled conditions for six hours on the first and last day of treatment. Budesolv contains 10 μg / spray which is approximately 85% less amount of active ingredient than the comparator product (64 μg / spray).